Skip to main content
Premium Trial:

Request an Annual Quote

French Bioinformatics Firm Ariana Pharma Raises $2.3M in VC Funding

NEW YORK (GenomeWeb News) - Ariana Pharma, a Paris-based provider of drug discovery software tools, said today that it has raised €1.5 million ($2.3 million) through a private placement.
 
Vizille Capital Innovation, a subsidiary of the Crédit Mutuel - CIC bank, was the sole investor in the round and gained a minority stake in the firm. VCI joins Ariana's existing shareholders, the Pasteur Institute and company management.
 
Ariana was founded in 2003 and has been self-funded until now. Its flagship product, called KEM, for knowledge extraction and management, is a data-mining software platform that can “identify relations that link both molecular features and the results of early tests with the risk of adverse events,” the company said.
 
Ariana’s customers include Pfizer, GlaxoSmithKline, Novartis, and Lundbeck.
 
The company said it plans to use the new funding to strengthen its sales and marketing efforts and to add new functionality to KEM that will “enhance its use in clinical trials and drug safety domains, interfacing with current industry standards and providing the new ability to detect early signals.”

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.